Summary Background Nowadays, the use of bisphosphonates is common. Bisphosphonates play an important role in the therapy and precaution of osteoporosis. The use of bisphosphonates may have concerned with cancer, especially oesophageal and gastric cancer. Nevertheless, whether bisphosphonates would cause oesophageal cancer have not been determined. Methods Two investigators independently selected correlative studies via PubMed, Embase and Cochrane Database in February 2020. No language restriction in our searched strategy. The random effects were used to calculate the pooled odds ratio (OR) and 95% confidence intervals (CI) for the risk of oesophageal cancer in bisphosphonate users compared with non‐users and the adjusted effect size would be used to calculate the combined effect size. We utilised the Egger's regression model to qualify publication bias. The sensitivity analyses were performed in our study to examine the stability of the results. We proceeded in a particular meta‐analysis of observational studies in the relationship between bisphosphonates or alendronate and carcinoma of the oesophagus. Result Finally, there were 10 studies being included in our meta‐analysis. Among them, there were six nested case‐control studies and four cohort studies. Preliminary analysis showed that the use of bisphosphonates was not associated with oesophageal cancer in both nested case‐control group (OR 1.07, 95% CI 0.92‐1.23) and cohort study (OR 0.82, 95% CI 0.63‐1.06). There was no heterogeneity in cohort studies or nested case‐control studies. No significant OR was found in the analyses of continents, women, alendronate and histologic types of oesophageal carcinoma. Conclusion According to the current analysis, the use of bisphosphonates was not associated with the development of oesophageal cancer.
Background: Fidgetin-like 1 (FIGNL1), a subfamily member of ATPases, is associated with diverse cellular activities (AAA proteins). FIGNL1 is involved in DNA repair. However, the latest study has indicated that FIGNL1 plays a crucial role in the occurrence and development of malignant tumors. Methods: FIGNL1 expression was analyzed via Oncomine and GEPIA databases, and its prognostic potential was analyzed using OncoLnc, UALCAN, and GEPIA databases. Moreover, the promoter methylation of FIGNL1 was analyzed through the UALCAN database. FIGNL1-related gene network was found within STRING. Gene Ontology (GO) annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were investigated across WebGestalt. FIGNL1 correlation with cancer immune infiltrates was estimated using the Tumor Immune Estimation Resource (TIMER) database. Results: We found that FIGNL1 is widely overexpressed in multiple human cancers, and its high expression was correlated with the poor prognosis of patients with kidney renal clear-cell carcinoma (KIRP), low-grade glioma (LGG) of brain, and liver hepatocellular carcinoma (LIHC). Additionally, the promoter methylation level of FIGNL1 showed a statistical significance between normal and primary tissues in KIRP and LGG via the UALCAN (P < 0.0001). FIGNL1 expression was highly correlated with the infiltrating levels of CD8+ T and CD4+ T cells, dendritic cells (DCs), macrophages, and neutrophils in LIHC. Conclusions: In this study, the correlation of FIGNL1 expression with the prognosis, promoter methylation, and immune infiltrates in KIRP, LGG, and LIHC was revealed. These findings suggested that FIGNL1 promised to be a prognostic biomarker for KIRP, LGG, and LIHC.
The association between the use of bisphosphonates (BPs) and the risk of lung cancer has been concerned recently. There is no explicit study indicating that whether the use of BPs would affect the risk of lung cancer. So, we conducted a meta-analysis to figure out the relationship between BPs and lung cancer. We searched the databases of PubMed and Embase. The random effects were used to calculate the pooled odds ratios (ORs) and 95% confidence interval (CIs) for the risk of lung cancer in BPs users compared with non-users. The stability of our results was evaluated by the sensitivity analysis. The publication bias was assessed in our study. The data in our study comes from the public database, therefore ethical approval is not necessary. Also, our study did not involve patient consent. Four studies met our inclusion criteria. All the included studies are cohort studies. Our analysis indicated that there was no significant association between the use of BPs and the risk of lung cancer (OR 1.02, 95%CI 0.85- 1.24, I 2 71%). In our secondary analysis, the use of alendronate may increase the risk of lung cancer. The pooled OR of 3 studies is (OR 1.10, 95%CI 0.84–1.45, I 2 77%), but when we performed a sensitivity analysis, 1 of the OR is (OR 1.23, 95%CI 1.02–1.49, I 2 4.1%). This is the most detailed meta-analysis on this topic. And there was no significant association between the use of BPs and lung cancer. However, exposure to alendronate may increase the risk of lung cancer. More studies are needed to confirm our findings.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.